United Immunity
Japan · Biotech
A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue.
Targeting immune cells inside the body
United Immunity’s Myeloid Targeting Platform uses two pullulan-based nanoparticle technologies: PNP for small molecules, peptides and proteins, and PEG-free P-LNP for nucleic acids such as mRNA and DNA. The particles are designed to deliver therapeutic payloads to macrophages and dendritic cells, including cells in diseased tissues.
The platform supports programs in cancer and other immune-related diseases. Its lead program, UI-102, is a PNP-encapsulated TLR7/8 agonist being evaluated in a Phase 1/2 clinical trial for advanced solid tumors; the company is also developing in-vivo macrophage-engineering approaches.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Private financing | ¥2.2B | Aozora HYBRID Fund III — ParticipantFujita TT Impact Fund I — ParticipantITOCHU Corporation — ParticipantJoyo Bank, Ltd. — ParticipantKobe University Fund I — ParticipantMitsubishi UFJ Life Sciences Fund II — ParticipantMiyako Kyoto University Innovation Fund III — ParticipantMizuho Life Sciences Fund I — ParticipantNVCC Fund 10 — ParticipantOno Venture Investment, Inc. — ParticipantRicoh Biomedical Startup Investment Limited Partnership — ParticipantSaisei Bioventures L.P. — ParticipantUTEC Fund V Limited Partnership — Participant |